Literature DB >> 8170551

Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.

R Tawil1, R T Moxley, R C Griggs.   

Abstract

Carbonic anhydrase inhibitors can cause nephrolithiasis. We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia. Three patients on acetazolamide (15%) developed renal calculi. Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment. Renal function remained normal in all patients. Nephrolithiasis is a complication of acetazolamide but does not preclude its use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8170551     DOI: 10.1212/wnl.43.6.1105

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Idiopathic Intracranial Hypertension.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Channelopathies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

3.  Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.

Authors:  Elahna Paul; Kerry D Conant; Irie E Dunne; Heidi H Pfeifer; David A Lyczkowski; Michael A Linshaw; Elizabeth A Thiele
Journal:  Epilepsy Res       Date:  2010-05-13       Impact factor: 3.045

Review 4.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 5.  Management of essential tremor.

Authors:  Theresa A Zesiewicz; Elmyra Encarnacion; Robert A Hauser
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 6.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Skeletal Muscle Channelopathies.

Authors:  Lauren Phillips; Jaya R Trivedi
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

8.  Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.

Authors:  Fenfen Wu; Wentao Mi; Stephen C Cannon
Journal:  Brain       Date:  2013-10-18       Impact factor: 13.501

9.  Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management.

Authors:  Matthew J Thurtell; Michael Wall
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

10.  Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.

Authors:  Valeria A Sansone; James Burge; Michael P McDermott; Patty C Smith; Barbara Herr; Rabi Tawil; Shree Pandya; John Kissel; Emma Ciafaloni; Perry Shieh; Jeffrey W Ralph; Antony Amato; Steve C Cannon; Jaya Trivedi; Richard Barohn; Brian Crum; Hiroshi Mitsumoto; Alan Pestronk; Giovanni Meola; Robin Conwit; Michael G Hanna; Robert C Griggs
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.